Mechelen, Belgium; March 117, 2026, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received a transparency notification from Bank of America.

Pursuant to Belgian transparency legislation¹, Galapagos received transparency notification from Bank of America Corporation on March 12, 2026. The notification indicates that Bank of America Corporation, as controlling entity, fell below the 5% threshold for of Galapagos' voting rights on March 10, 2026, as a result of the disposal of equivalent financial instruments relating to Galapagos' voting rights.

On March 12, 2026, Bank of America Corporation (taking into account the holding of its affiliates) owned 421,092 voting rights and 2,158,293 equivalent financial instruments, representing together 3.91% of Galapagos' currently outstanding 65,897,071 shares.

Summary of the transactions:

Date on which the threshold was crossed	Date of notification	Direct voting rights after the transaction	Equivalent financial instruments after the transaction	Total (%) voting rights
March 10, 2026	March 12, 2026	0.64%	3.28%	3.91%

Content of the notifications from Bank of America Corporation:

The notification dated March 12, 2026, contains the following information:

Date of notification: March 12, 2026
Date on which the threshold is crossed: March 10, 2026
Threshold of voting rights crossed (in %): 5%
Notification by: Bank of America Corporation
Denominator: 65,897,071
Reason for the notification: Acquisition or disposal of financial instruments that are treated as voting securities
Notified details:

A) Voting Rights	Previous notification	After the transaction
	# of voting rights	# of voting rights		% of voting rights
Holder of voting rights		Linked to securities	Not linked to securities	Linked to securities	Not linked to securities
Bank of America Corporation	0	0		0.00%
Bank of America, National Association	12,440	12,447		0.02%
Merrill Lynch International	128,053	225,319		0.34%
Managed Account Advisors LLC	3	3		0.00%
BofA Securities, Inc.	180,123	168,740		0.26%
Merrill Lynch, Pierce, Fenner & Smith Incorporated	14,462	14,462		0.02%
U.S. Trust Company of Delaware	121	121		0.00%
Subtotal	335,202	421,092		0.64%
	TOTAL	421,092	0	0.64%	0.00%

B) Equivalent financial instruments	After the transaction
Holder of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
Merrill Lynch International	Right to Recall			111,582	0.17%	physical
Merrill Lynch International	Rights of Use			6,579	0.01%	physical
BofA Securities, Inc.	Right to Recall			11,500	0.02%	physical
BofA Securities, Inc.	Rights of Use			1,876,489	2.85%	physical
Merrill Lynch International	Physical Call Option	19/06/2026		100,000	0.15%	physical
Bank of America, National Association	Swaps	15/04/2027		12,214	0.02%	cash
Bank of America, National Association	Swaps	29/02/2028		843	0.00%	cash
Bank of America, National Association	Swaps	15/10/2027		5	0.00%	cash
Merrill Lynch International	Swaps	15/01/2027		8,056	0.01%	cash
Merrill Lynch International	Swaps	30/04/2026		8,240	0.01%	cash
Merrill Lynch International	Swaps	02/07/2026		592	0.00%	cash
Merrill Lynch International	Swaps	01/11/2027		5,217	0.01%	cash
Merrill Lynch International	Swaps	15/04/2027		12,214	0.02%	cash
Merrill Lynch International	Swaps	30/06/2026		3,108	0.00%	cash
Merrill Lynch International	Swaps	31/03/2027		950	0.00%	cash
Merrill Lynch International	Swaps	29/01/2027		704	0.00%	cash
	TOTAL			2,158,293	3.28%

TOTAL (A&B)	# of voting rights	% of voting rights
	2,579,385	3.91%

The chain of control has been described at the end of the notification (section 11) and can be found here.

About Galapagos

Galapagos is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Galapagos prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas. For more information, visit www.glpg.com or follow us on LinkedIn or X.

For further information, contact Galapagos:

Investor Relations

Glenn Schulman

+1 412 522 6239

ir@glpg.com

Media

Media

Katie Morris

+1 952 288 6821

katiemorris@ententeinc.com

¹ Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions, as amended from time to time.

Attachment

Galapagos Receives Transparency Notification from Bank of America

Galapagos Receives Transparency Notification from Bank of America